New hope for tough lung cancers: quadruple therapy targets resistant tumors
NCT ID NCT07416058
First seen Feb 27, 2026 · Last updated May 20, 2026 · Updated 8 times
Summary
This study tests a combination of four drugs (QL1706, bevacizumab, and two chemotherapy drugs) in people with advanced non-squamous lung cancer whose tumors have specific gene changes and have stopped responding to targeted therapy. The goal is to see if this treatment can shrink tumors better than standard chemotherapy alone. About 61 adults with high PD-L1 levels will receive the treatment every 3 weeks for up to 2 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.